Estrella Immunopharma Stock Current Ratio
| ESLAW Stock | 0.09 0 1.10% |
Estrella Immunopharma fundamentals help investors to digest information that contributes to Estrella Immunopharma's financial success or failures. It also enables traders to predict the movement of Estrella Stock. The fundamental analysis module provides a way to measure Estrella Immunopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Estrella Immunopharma stock.
| Last Reported | Projected for Next Year | ||
| Current Ratio | 24.65 | 0.05 |
Estrella | Current Ratio |
Estrella Immunopharma Company Current Ratio Analysis
Estrella Immunopharma's Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Current Estrella Immunopharma Current Ratio | 0.0489 |
Most of Estrella Immunopharma's fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Estrella Immunopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Estrella Current Ratio Driver Correlations
Understanding the fundamental principles of building solid financial models for Estrella Immunopharma is extremely important. It helps to project a fair market value of Estrella Stock properly, considering its historical fundamentals such as Current Ratio. Since Estrella Immunopharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Estrella Immunopharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Estrella Immunopharma's interrelated accounts and indicators.
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
| Competition |
Estrella Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Estrella Immunopharma's direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Estrella Immunopharma could also be used in its relative valuation, which is a method of valuing Estrella Immunopharma by comparing valuation metrics of similar companies.Estrella Immunopharma is currently under evaluation in current ratio category among its peers.
Estrella Fundamentals
| Return On Asset | -1.75 | ||||
| Number Of Shares Shorted | 22.44 K | ||||
| EBITDA | (7.31 M) | ||||
| Net Income | (7.31 M) | ||||
| Total Debt | 180.7 K | ||||
| Book Value Per Share | (2.89) X | ||||
| Cash Flow From Operations | (16.07 M) | ||||
| Beta | -0.09 | ||||
| Total Asset | 4.45 M | ||||
| Retained Earnings | (19.5 M) | ||||
| Working Capital | 4.27 M | ||||
| Net Asset | 4.45 M |
About Estrella Immunopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Estrella Immunopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Estrella Immunopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Estrella Immunopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Estrella Stock Analysis
When running Estrella Immunopharma's price analysis, check to measure Estrella Immunopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Estrella Immunopharma is operating at the current time. Most of Estrella Immunopharma's value examination focuses on studying past and present price action to predict the probability of Estrella Immunopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Estrella Immunopharma's price. Additionally, you may evaluate how the addition of Estrella Immunopharma to your portfolios can decrease your overall portfolio volatility.